Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$125.00 USD

125.00
4,512,532

-0.59 (-0.47%)

Updated May 3, 2024 04:00 PM ET

After-Market: $125.10 +0.10 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Moderna (MRNA)

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.

Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session.

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?

Smart Beta ETF report for QQEW

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Moderna (MRNA) Stock Moves -0.58%: What You Should Know

Moderna (MRNA) reachead $101.41 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.

Moderna (MRNA) Stock Moves -0.34%: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News

Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Company News for Apr 10, 2024

Companies in The News Are: MRNA, MRK, COIN, BN, NEOG

Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.